Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis — Hira Mian (2025) | RDL Network
Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis
Yi Lin, Sireesha Asoori Maringanti, Efstathios Kastritis, Joaquín Martínez‐López, Larissa Brunaldi, Radhika Bansal, Despina Fotiou, Magdelana Corona, Reyes Mas, Andre De Menezes Silva Corraes, Prashant Kapoor, Meletios A Dimopoulos, Andre Tamayo, Sikander Ailawadhi, Ricardo Parrondo, Brian G.M. Durie, Thomas G. Martin
Kwan Hung Ng, Gloria H W Lau, Ka Man Yu, Jenny S. W. Lee, Suyi Xie, Leong-Ting Lui, Lihua Huang, Tung Wai Auyeung, Jean Woo, Alice P.S. Kong, Ronald C.W., Juliana C.N. Chan, Petri Wiklund, Ville‐Petteri Mäkinen, Paul M Ridker, Cecilia Lo, Stephan Beck, Simone Ecker, Erik Fung
Discussion(0)
No comments yet. Be the first to comment.